Project B13
Improvement and dissemination of molecular imaging and therapy of adrenocortical tumours
In the third funding period, subproject B13 aims to optimise and expand established theranostic radiopharmaceuticals for the diagnosis and treatment of adrenal cortical tumours, in particular adrenal cortical carcinoma (ACC). Building on the successful clinical introduction of CYP11B- and CYP17-targeted radiopharmaceuticals, the focus is on the development of radiofluorinated derivatives of IMAZA and IPIMA for PET imaging with improved image quality and simplified cross-site implementation.
In parallel, the endoradiotherapeutic application of [¹³¹I]IMAZA is being further optimised by investigating intratumoural kinetics, mechanisms of radiation-induced cell damage and potentially synergistic therapeutic strategies. In addition, the development of boronated IMAZA and IPIMA derivatives is being evaluated as an innovative alternative therapeutic approach for ACC using boron neutron capture therapy (BNCT).
| Principal Investigators | Institution |
| Prof. Dr. med. Stefanie Hahner | JMU |
| Dr. rer. nat. Andreas Schirbel | JMU |
